Sort
48,018 grants matching “immunotherapy”
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
$396,771Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
$396,771Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
$396,771Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2018 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication
$396,737Yong Lu · Methodist Hospital Research Institute · R01 · FY2025 · CA
Use of a novel physiologic measure for the assessment and monitoring of vincristine induced peripheral neuropathy (VIPN) in children and adolescents.
$396,711Kevin Jackson · Algometrx, Inc. · R43 · FY2022 · CA
New Peptides for the Treatment of Multiple Sclerosis
$396,708Christine Beeton · Baylor College Of Medicine · R01 · FY2011 · NS
Stromal metabolism promotes therapeutic resistance in pancreatic cancer
$396,684Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
$396,679Esak Lee · Cornell University · R01 · FY2025 · CA
Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)
$396,664Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
$396,625Aaron N Hata · Massachusetts General Hospital · R01 · FY2024 · CA
Investigation of the Cellular and Molecular Mechanisms of Thrombocyte Integrin Signaling
$396,600Zhao Wang · Baylor College Of Medicine · R01 · FY2023 · HL
Investigation of the Cellular and Molecular Mechanisms of Thrombocyte Integrin Signaling
$396,600Zhao Wang · Baylor College Of Medicine · R01 · FY2025 · HL
Investigation of the Cellular and Molecular Mechanisms of Thrombocyte Integrin Signaling
$396,600Zhao Wang · Baylor College Of Medicine · R01 · FY2024 · HL
Strategies for Receptor inhibition in immunotherapy
$396,586Kenan Christopher Garcia · Stanford University · R01 · FY2021 · CA
High-Specificity Imaging Agents for Aggressive Prostate Cancer
$396,577Martin G Pomper · Johns Hopkins University · R01 · FY2018 · CA
Metabolic regulation of exosome biogenesis as a determinant of cancer cell metastasis.
$396,573Marc A Antonyak · Cornell University · R01 · FY2024 · CA
SOUTHWEST ONCOLOGY GROUP
$396,518Swedish Medical Center, First Hill · U10 · FY2001 · CA
Follicular Regulatory T-cells Promote Cancer
$396,483Jianmei Wu Leavenworth · University Of Alabama At Birmingham · R01 · FY2023 · CA
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING
$396,453Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
$396,432Brent Allen Hanks · Duke University · R01 · FY2021 · CA
Improved Treatment of Colorectal Cancer with CF10
$396,429William H Gmeiner · Deep Creek Pharma, Llc · R41 · FY2021 · CA
Strategies to Enhance Adoptive Transfer T Cell Clones
$396,427Stanley R Riddell · Fred Hutchinson Cancer Research Center · R01 · FY2009 · CA
Accelerated CD8 T cell memory after DC vaccination
$396,424John T. Harty · University Of Iowa · R01 · FY2010 · AI
Core 1: Tumor Processing and Single Cell RNA sequencing Core
$396,400Kai W Wucherpfennig · Brigham And Women'S Hospital · P01 · FY2020 · CA
Regulation of Natural Killer Cell Activation Receptors, NKG2D and CD16
$396,396John Coligan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI